Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess

E. Seeman, Rajiv Kumar, G. G. Hunder, M. Scott, H. Heath IIIrd, B. L. Riggs

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

The decreased intestinal absorption of calcium and accelerated bone loss associated with chronic glucocorticoid excess may be mediated by changes in vitamin D metabolism, leading to decreased availability of circulating 1,25-dihydroxyvitamin D. This hypothesis was examined in 14 patients with either endogenous or exogenous glucocorticoid excess. Analysis of paired serum samples (mean±SE) in 13 patients during euglucocorticoidism and during hyperglucocorticoidism showed that glucocorticoid excess resulted in small decreases of plasma 25-hydroxyvitamin D concentrations (22±2- 18±2 ng/ml; P < 0.05) but no significant changes in plasma 1,25-dihydroxyvitamin D (32±8-23±6 pg/ml) or serum immunoreactive parathyroid hormone (21±2-18±2 μleq/ml). Additionally, we studied plasma kinetics of [ 3H]1,25-dihydroxyvitamin D 3 after intravenous bolus administration in 10 hyperglucocorticoid patients and in 14 normal controls. Assessment with a three compartment model showed no significant abnormalities in production rates (hyperglucocorticoid patients 1.2±0.3 μg/d, controls 1.5±0.2 μg/d) or metabolic clearance rates (hyperglucocorticoid patients, 32±3 ml/min; controls, 31±3 ml/min). Moreover, there were no significant differences in cumulative excretion of radioactivity in urine (hyperglucocorticoid patients, 18±2%; controls, 14±2%) or feces (hyperglucocorticoid patients, 60±9%, controls, 54±6%). We conclude that glucocorticoid excess does not effect plasma levels, production, or degradation of 1,25(OH) 2D in humans. Thus, other mechanisms must be postulated to explain satisfactorily the abnormalities of bone structure and intestinal calcium absorption that may occur after chronic glucocorticoid therapy.

Original languageEnglish (US)
Pages (from-to)664-669
Number of pages6
JournalJournal of Clinical Investigation
Volume66
Issue number4
StatePublished - 1980

Fingerprint

Glucocorticoids
Health
Intestinal Absorption
Metabolic Clearance Rate
Calcium
Bone and Bones
1,25-dihydroxyvitamin D
Parathyroid Hormone
Serum
Feces
Vitamin D
Intravenous Administration
Radioactivity
Urine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess. / Seeman, E.; Kumar, Rajiv; Hunder, G. G.; Scott, M.; Heath IIIrd, H.; Riggs, B. L.

In: Journal of Clinical Investigation, Vol. 66, No. 4, 1980, p. 664-669.

Research output: Contribution to journalArticle

Seeman, E. ; Kumar, Rajiv ; Hunder, G. G. ; Scott, M. ; Heath IIIrd, H. ; Riggs, B. L. / Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess. In: Journal of Clinical Investigation. 1980 ; Vol. 66, No. 4. pp. 664-669.
@article{0674b303c2474bd995d87fbfd1c0375c,
title = "Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess",
abstract = "The decreased intestinal absorption of calcium and accelerated bone loss associated with chronic glucocorticoid excess may be mediated by changes in vitamin D metabolism, leading to decreased availability of circulating 1,25-dihydroxyvitamin D. This hypothesis was examined in 14 patients with either endogenous or exogenous glucocorticoid excess. Analysis of paired serum samples (mean±SE) in 13 patients during euglucocorticoidism and during hyperglucocorticoidism showed that glucocorticoid excess resulted in small decreases of plasma 25-hydroxyvitamin D concentrations (22±2- 18±2 ng/ml; P < 0.05) but no significant changes in plasma 1,25-dihydroxyvitamin D (32±8-23±6 pg/ml) or serum immunoreactive parathyroid hormone (21±2-18±2 μleq/ml). Additionally, we studied plasma kinetics of [ 3H]1,25-dihydroxyvitamin D 3 after intravenous bolus administration in 10 hyperglucocorticoid patients and in 14 normal controls. Assessment with a three compartment model showed no significant abnormalities in production rates (hyperglucocorticoid patients 1.2±0.3 μg/d, controls 1.5±0.2 μg/d) or metabolic clearance rates (hyperglucocorticoid patients, 32±3 ml/min; controls, 31±3 ml/min). Moreover, there were no significant differences in cumulative excretion of radioactivity in urine (hyperglucocorticoid patients, 18±2{\%}; controls, 14±2{\%}) or feces (hyperglucocorticoid patients, 60±9{\%}, controls, 54±6{\%}). We conclude that glucocorticoid excess does not effect plasma levels, production, or degradation of 1,25(OH) 2D in humans. Thus, other mechanisms must be postulated to explain satisfactorily the abnormalities of bone structure and intestinal calcium absorption that may occur after chronic glucocorticoid therapy.",
author = "E. Seeman and Rajiv Kumar and Hunder, {G. G.} and M. Scott and {Heath IIIrd}, H. and Riggs, {B. L.}",
year = "1980",
language = "English (US)",
volume = "66",
pages = "664--669",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess

AU - Seeman, E.

AU - Kumar, Rajiv

AU - Hunder, G. G.

AU - Scott, M.

AU - Heath IIIrd, H.

AU - Riggs, B. L.

PY - 1980

Y1 - 1980

N2 - The decreased intestinal absorption of calcium and accelerated bone loss associated with chronic glucocorticoid excess may be mediated by changes in vitamin D metabolism, leading to decreased availability of circulating 1,25-dihydroxyvitamin D. This hypothesis was examined in 14 patients with either endogenous or exogenous glucocorticoid excess. Analysis of paired serum samples (mean±SE) in 13 patients during euglucocorticoidism and during hyperglucocorticoidism showed that glucocorticoid excess resulted in small decreases of plasma 25-hydroxyvitamin D concentrations (22±2- 18±2 ng/ml; P < 0.05) but no significant changes in plasma 1,25-dihydroxyvitamin D (32±8-23±6 pg/ml) or serum immunoreactive parathyroid hormone (21±2-18±2 μleq/ml). Additionally, we studied plasma kinetics of [ 3H]1,25-dihydroxyvitamin D 3 after intravenous bolus administration in 10 hyperglucocorticoid patients and in 14 normal controls. Assessment with a three compartment model showed no significant abnormalities in production rates (hyperglucocorticoid patients 1.2±0.3 μg/d, controls 1.5±0.2 μg/d) or metabolic clearance rates (hyperglucocorticoid patients, 32±3 ml/min; controls, 31±3 ml/min). Moreover, there were no significant differences in cumulative excretion of radioactivity in urine (hyperglucocorticoid patients, 18±2%; controls, 14±2%) or feces (hyperglucocorticoid patients, 60±9%, controls, 54±6%). We conclude that glucocorticoid excess does not effect plasma levels, production, or degradation of 1,25(OH) 2D in humans. Thus, other mechanisms must be postulated to explain satisfactorily the abnormalities of bone structure and intestinal calcium absorption that may occur after chronic glucocorticoid therapy.

AB - The decreased intestinal absorption of calcium and accelerated bone loss associated with chronic glucocorticoid excess may be mediated by changes in vitamin D metabolism, leading to decreased availability of circulating 1,25-dihydroxyvitamin D. This hypothesis was examined in 14 patients with either endogenous or exogenous glucocorticoid excess. Analysis of paired serum samples (mean±SE) in 13 patients during euglucocorticoidism and during hyperglucocorticoidism showed that glucocorticoid excess resulted in small decreases of plasma 25-hydroxyvitamin D concentrations (22±2- 18±2 ng/ml; P < 0.05) but no significant changes in plasma 1,25-dihydroxyvitamin D (32±8-23±6 pg/ml) or serum immunoreactive parathyroid hormone (21±2-18±2 μleq/ml). Additionally, we studied plasma kinetics of [ 3H]1,25-dihydroxyvitamin D 3 after intravenous bolus administration in 10 hyperglucocorticoid patients and in 14 normal controls. Assessment with a three compartment model showed no significant abnormalities in production rates (hyperglucocorticoid patients 1.2±0.3 μg/d, controls 1.5±0.2 μg/d) or metabolic clearance rates (hyperglucocorticoid patients, 32±3 ml/min; controls, 31±3 ml/min). Moreover, there were no significant differences in cumulative excretion of radioactivity in urine (hyperglucocorticoid patients, 18±2%; controls, 14±2%) or feces (hyperglucocorticoid patients, 60±9%, controls, 54±6%). We conclude that glucocorticoid excess does not effect plasma levels, production, or degradation of 1,25(OH) 2D in humans. Thus, other mechanisms must be postulated to explain satisfactorily the abnormalities of bone structure and intestinal calcium absorption that may occur after chronic glucocorticoid therapy.

UR - http://www.scopus.com/inward/record.url?scp=0018894388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018894388&partnerID=8YFLogxK

M3 - Article

C2 - 7419714

AN - SCOPUS:0018894388

VL - 66

SP - 664

EP - 669

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -